These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9544433)
1. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Abdel-Rahman SZ; Anwar WA; Abdel-Aal WE; Mostafa HM; Au WW Cancer Detect Prev; 1998; 22(2):129-38. PubMed ID: 9544433 [TBL] [Abstract][Full Text] [Related]
2. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357 [TBL] [Abstract][Full Text] [Related]
3. Polymorphism of GSTM1 and GSTT1 genes in bladder cancer: a study from North India. Srivastava DS; Kumar A; Mittal B; Mittal RD Arch Toxicol; 2004 Aug; 78(8):430-4. PubMed ID: 15057507 [TBL] [Abstract][Full Text] [Related]
4. GSTM1, GSTT1 null variants, and GPX1 single nucleotide polymorphism are not associated with bladder cancer risk in Egypt. Goerlitz D; El Daly M; Abdel-Hamid M; Saleh DA; Goldman L; El Kafrawy S; Hifnawy T; Ezzat S; Abdel-Aziz MA; Zaghloul MS; Ali SR; Khaled H; Amr S; Zheng YL; Mikhail N; Loffredo C Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1552-4. PubMed ID: 21586620 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers. Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921 [TBL] [Abstract][Full Text] [Related]
7. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study. Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358 [TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Anwar WA; Abdel-Rahman SZ; El-Zein RA; Mostafa HM; Au WW Carcinogenesis; 1996 Sep; 17(9):1923-9. PubMed ID: 8824515 [TBL] [Abstract][Full Text] [Related]
9. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer. Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789 [TBL] [Abstract][Full Text] [Related]
10. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer. Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828 [TBL] [Abstract][Full Text] [Related]
11. CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population. Berber U; Yilmaz I; Yilmaz O; Haholu A; Kucukodaci Z; Ates F; Demirel D Asian Pac J Cancer Prev; 2013; 14(6):3925-9. PubMed ID: 23886208 [TBL] [Abstract][Full Text] [Related]
12. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722 [TBL] [Abstract][Full Text] [Related]
13. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. Bell DA; Taylor JA; Paulson DF; Robertson CN; Mohler JL; Lucier GW J Natl Cancer Inst; 1993 Jul; 85(14):1159-64. PubMed ID: 8320745 [TBL] [Abstract][Full Text] [Related]
14. The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients. Cengiz M; Ozaydin A; Ozkilic AC; Dedekarginoglu G Int Urol Nephrol; 2007; 39(4):1043-8. PubMed ID: 17340208 [TBL] [Abstract][Full Text] [Related]
15. The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Abdel-Rahman SZ; Anwar WA; Abdel-Aal WE; Ghoneim MA; Au WW Cancer Lett; 1997 Oct; 119(1):115-22. PubMed ID: 18372530 [TBL] [Abstract][Full Text] [Related]
16. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301 [TBL] [Abstract][Full Text] [Related]
17. The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population. Ouerhani S; Tebourski F; Slama MR; Marrakchi R; Rabeh M; Hassine LB; Ayed M; Elgaaïed AB Ann Hum Biol; 2006; 33(5-6):529-35. PubMed ID: 17381051 [TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Törüner GA; Akyerli C; Uçar A; Aki T; Atsu N; Ozen H; Tez M; Cetinkaya M; Ozçelik T Arch Toxicol; 2001 Oct; 75(8):459-64. PubMed ID: 11757669 [TBL] [Abstract][Full Text] [Related]
19. The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. Salagovic J; Kalina I; Habalová V; Hrivnák M; Valanský L; Biros E Physiol Res; 1999; 48(6):465-71. PubMed ID: 10783912 [TBL] [Abstract][Full Text] [Related]